Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit

Atherosclerosis
S PanagiotopoulosG Jerums

Abstract

Advanced glycosylation endproducts (AGEs) which result from the non-enzymatic interaction of proteins and glucose are implicated in the vasculopathy of diabetes and aging. Since aminoguanidine (A) inhibits the accumulation of AGEs, we explored its effects on the development of atherosclerosis. Male New Zealand white cross rabbits fed a high cholesterol (1%) diet were randomized to control (C) or increasing doses of A treatment (25, 50 and 100 mg/kg A body weight). The animals were sacrificed after 12 weeks. Sudan IV was used to stain the lipid containing plaques of the aortic arch, thoracic and abdominal aorta and the surface area occupied by atheroma was assessed. Increasing doses of A treatment were associated with reduction in plaque formation in the aorta. At a dose of 100 mg/kg A, there was a 30, 49 and 48% reduction in plaque formation in the aortic arch, thoracic and abdominal aorta, respectively. There was a correlation between AGE levels and the degree of atheroma in these cholesterol fed rabbits (control, r = 0.75, P < 0.01; 100 mg/kg A, r = 0.59, P = 0.02). These data suggest that advanced glycation may participate in atherogenesis and raise the possibility that inhibitors of advanced glycation may retard this process.

References

Feb 1, 1992·Journal of Cardiovascular Pharmacology·B Q ZhuW W Parmley
Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·H VlassaraR Bucala
Sep 1, 1992·The Journal of Clinical Investigation·J P CookeM E Billingham
Apr 1, 1992·Diabetes Research and Clinical Practice·M Z Gilcrease, R L Hoover
Dec 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·H P HammesM Brownlee
May 19, 1988·The New England Journal of Medicine·M BrownleeH Vlassara
Oct 1, 1971·Comparative Biochemistry and Physiology. B, Comparative Biochemistry·G L Mills, C E Taylaur
Jun 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·U P SteinbrecherD Steinberg
Nov 1, 1981·The Journal of Clinical Investigation·P D Henry, K I Bentley
Nov 1, 1980·The Journal of Clinical Investigation·S L Schnider, R R Kohn
May 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·A J CayatteR A Cohen
May 1, 1993·Journal of Cardiovascular Pharmacology·T J VerbeurenS Simonet
May 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·W PalinskiJ L Witztum
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·R BucalaH Vlassara
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·H VlassaraM Steffes
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·R BucalaH Vlassara
Feb 25, 1993·The American Journal of Cardiology·T J Lyons
Jan 25, 1993·Atherosclerosis·W K LeeM H Dominiczak

❮ Previous
Next ❯

Citations

Apr 13, 2011·Cellular and Molecular Neurobiology·Mohsen AlipourMaryam Pourheidar
Feb 7, 2004·Current Diabetes Reports·Melpomeni PeppaHelen Vlassara
Aug 12, 1999·European Journal of Pharmacology·H BultK E Matthys
Aug 18, 2000·Free Radical Biology & Medicine·J W Baynes, S R Thorpe
May 17, 2011·Journal of Agricultural and Food Chemistry·Shih-Hao WangRobin Y-Y Chiou
Mar 22, 2002·Journal of Internal Medicine·H Vlassara, M R Palace
Feb 24, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Anna C Calkin, Terri J Allen
Dec 3, 2013·Current Diabetes Reports·Helen Vlassara, Jaime Uribarri
Sep 13, 2002·Expert Opinion on Investigational Drugs·Alan W StittMark E Cooper
Jun 20, 2006·British Journal of Pharmacology·Vincent ChanLindsay Brown
May 10, 2008·Cardiovascular Therapeutics·Sho-ichi YamagishiTsutomu Imaizumi
Jan 5, 2002·Expert Opinion on Investigational Drugs·S VasanH W Founds
Jul 12, 2003·Eye·M Donaldson, P M Dodson
Feb 28, 2007·British Journal of Cancer·A M E BruynzeelW J F van der Vijgh
Jun 29, 2007·The Journal of Pharmacology and Experimental Therapeutics·Michael KazachkovPeter H Yu
Jan 9, 2010·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Sandra Müller-KrebsVedat Schwenger
Jun 30, 2019·Cellular and Molecular Life Sciences : CMLS·Ting-Wei LeeTing-I Lee
Sep 20, 2008·Free Radical Biology & Medicine·Sylvain GalvaniAnne Nègre-Salvayre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia Cerebrovascular Disease

Basal ganglia cerebrovascular disease is a condition where the blood vessels in the basal ganglia are damaged or malfunction. Discover the latest research on basal ganglia cerebrovascular disease here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.